Tenax Therapeutics Inc
TENX
Get informed when a big investor buys or sells
+ FollowMarket Cap$235.61M
Close$
$2.49
82% downside
Current Fair Value
82% downsideOvervalued by 82% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $235.61 Million |
|---|---|
| Enterprise Value | $117.63 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 0.91 |
| Outstanding Shares | 50,869,259 |
Return
| Return on Equity | -57.10% |
|---|---|
| Return on Assets | -53.31% |
| Return on Invested Capital | 4.12% |
Valuation & Multiples
| P/E Ratio | -9.19 |
|---|---|
| PEG | -14.34 |
| Price to Sales | - |
| Price to Book Ratio | 6.91 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 25.12 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 147,400▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.12%▲ 36.40% |
|---|---|
| Total Invested | $339.42M▲ 300.75% |
| Investors Holding | 81▲ 33.00% |
ESG Score
No data
About Tenax Therapeutics Inc
CEO: John Kelley